# Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Study · id `cardio:ct-nct06260722` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06260722](<https://clinicaltrials.gov/study/NCT06260722>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06260722

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1250 participants.

## Technical summary

Registry record NCT06260722. Randomized; no masking; primary purpose treatment. Start 2024-02-21 (actual); primary completion 2026-08-27 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1250 participants (planned count; ClinicalTrials.gov record NCT06260722, source copy `cardio:ctgov-nct06260722-2026-09-28`, retrieved 2026-10-26)
- Started: 2024-02-21 (actual) (ClinicalTrials.gov record NCT06260722, source copy `cardio:ctgov-nct06260722-2026-09-28`, retrieved 2026-10-26)
- Primary completion: 2026-08-27 (actual) (ClinicalTrials.gov record NCT06260722, source copy `cardio:ctgov-nct06260722-2026-09-28`, retrieved 2026-10-26)
- Completion: 2027-02 (anticipated) (ClinicalTrials.gov record NCT06260722, source copy `cardio:ctgov-nct06260722-2026-09-28`, retrieved 2026-10-26)
- Countries: United States; Argentina; Canada; Mexico; Puerto Rico (ClinicalTrials.gov record NCT06260722, source copy `cardio:ctgov-nct06260722-2026-09-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06260722-2026-09-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Retatrutide
- Intervention (Drug): Semaglutide
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 13def72c6f555fd803b5ca08b71db4df35f45868a62d2f10f75fdd7eb2fdeb39
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
